Ellagic Acid, Urolithin and Colonic Microbial Communities Affected by Walnut Consumption

Last updated: November 24, 2021
Sponsor: UConn Health
Overall Status: Completed

Phase

N/A

Condition

Colon Cancer

Rectal Cancer

Digestive System Neoplasms

Treatment

N/A

Clinical Study ID

NCT04066816
19-121JS-1
  • Ages 50-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Briefly, this is a 28-day dietary intervention study participants will be asked to eat 2 ounces (52 grams) of walnuts every day for 3 weeks, and at the end of the study period they will come in for a colonoscopy. Participants will first start a 1-week run-in period where they will be asked to avoid foods high in ellagic acid. In addition, they will be asked to complete food surveys and two sets of 3-day dietary records, and to provide colon biopsies for this study during their routine colonoscopy, as well as a blood, and two urine and stool samples. Urine samples will be used for analysis of urolithin, ellagic acid metabolites. Stool samples will be used to assess gut microbiota changes after walnut consumption. Dietary records will be used for compliance and Food Frequency Questionnaire will be used to assess dietary habits. Lastly, the biopsy samples will be used for analysis of biomarkers and anti-inflammatory in the colon, as well as adherent microbiome to the colonic tissue. Data will be analyzed based on the urolithin phenotypes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men or women between the ages of 50-65 years old who are scheduled to undergo aroutine screening colonoscopy
  • English speaking/reading patients willing and able to provide written informed consentfor study participation
  • Patients willing to consume walnuts for 3 weeks
  • Willingness to comply with all study requirements

Exclusion

Exclusion Criteria:

  • Current active malignancy, previous history of gastrointestinal malignancy, or alteredgastrointestinal anatomy
  • Current evidence or previous history of ulcerative colitis or Crohn's disease
  • HIV infection, chronic viral hepatitis
  • Allergy to walnuts or hypersensitivity to tree nuts
  • Use of antibiotics within the past month
  • Individuals with blood coagulation disorders or on anti-coagulant therapy
  • Treated with steroids, immunosuppressive agents or other anti-inflammatory drugs oneweek prior to starting intervention
  • Non-English-speaking patients who require an interpreter to give consent
  • Patients residing in the Department of Correction
  • Inability to comply with the protocol requirements
  • Any other condition that, in the opinion of the PI, might interfere with studyobjectives

Study Design

Total Participants: 47
Study Start date:
May 20, 2019
Estimated Completion Date:
April 08, 2021

Study Description

The investigators propose to address the influence of ellagic acid obtained from walnuts and its microbial-derived metabolites (urolithin) on the gut microbiome and inflammation-related biomarkers in a human clinical study. Patients will be enrolled and detailed demographic and dietary information, biopsy specimens through colonoscopies, as well as fecal, blood and urine samples will be collected. The wide range of gut urolithin levels provides the rationale for our proposed studies. Will the specific urolithin phenotypes show a disparate range of chemopreventive (anti-inflammatory) response to walnut consumption? The hypothesis is that walnut ingestion in "Phenotype A" participants (producing the highest levels of urolithin) will be associated with a beneficial anti-inflammatory response as tested in colonic mucosa and a higher abundance of bacterial species associated with ellagic acid metabolism. Although 16S ribosomal ribonucleic acid gene (rRNA) sequencing allows inexpensive bacterial identification at the genus/species level, a whole genome sequencing (mWGS) will be employed to achieve finer classification (strain level), and identify other microbes (e.g., viruses, fungi, small eukaryotes). Furthermore, mWGS targets the entire genome of each microbe (not just the 16S rRNA gene), allowing for construction of a microbial gene catalogue, including a metabolic pathway description for each sample. This will characterize the functional potential of the microbial community. Ultimately, the proposed studies will inform the application of prebiotic to enhance the formation of urolithin metabolites from ellagic acid for the prevention of inflammation-associated Colorectal Cancer, a development that would have significant translational implications.

Connect with a study center

  • University of Connecticut Health Center

    Farmington, Connecticut 06030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.